lipid peroxidation inhibitor

Subscribe to Selected New Research on lipid peroxidation inhibitor

29 relevant articles (1 outcomes, 5 trials/studies) found for this Bio-Agent

Description: a mixture of free carboxylic acids (major components comprising 92% of the total fatty acids); induced by CCl(4) in rat liver soluble fraction; also glutathione-dependent factor isolated from human red cell membrane

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13939

Fatty Acids: 4922

lipid peroxidation inhibitor: 29

Experts

1.	Håberg, A: 1 article (06/2007)
2.	Qu, H: 1 article (06/2007)
3.	Hjelstuen, M H: 1 article (06/2007)
4.	Sonnewald, U: 1 article (06/2007)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 02/01/1994 - "BACKGROUND AND PURPOSE: Tirilazad mesylate, a 21-amino-steroid, is a potent membrane lipid peroxidation inhibitor and free radical scavenger that has shown promise in animal models of focal cerebral ischemia. " 06/01/1998 - "Postischemic application of lipid peroxidation inhibitor U-101033E reduces neuronal damage after global cerebral ischemia in rats." 09/01/1996 - "BACKGROUND AND PURPOSE: Tirilazad mesylate, a nonglucocorticoid 21-aminosteroid lipid peroxidation inhibitor, has shown promise as a neuroprotectant in experimental models of focal cerebral ischemia. " 08/01/1988 - "21-Aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils." 06/01/1992 - "BACKGROUND AND PURPOSE: We examined the cytoprotective effect of the lipid peroxidation inhibitor tirilazad mesylate (U74006F) in rodent models of neocortical infarction induced by transient and permanent focal cerebral ischemia. " Order ALL the reference details at left...
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/04/1994 - "The aim of this study was to evaluate the effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, on ischaemic brain tissue damage using the rat middle cerebral artery occlusion model. " 01/04/1994 - "Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, in the rat middle cerebral artery occlusion model." 06/01/2007 - "The aim of the present study was to assess the effect of post ictal administration of the pyrrolopyrimidine lipid peroxidation inhibitor, U-101033E, on infarct volume and neuronal and astrocytic metabolism in rats with transient middle cerebral artery occlusion (MCAO). " 06/01/2007 - "Effect of the pyrrolopyrimidine lipid peroxidation inhibitor U-101033E on neuronal and astrocytic metabolism and infarct volume in rats with transient middle cerebral artery occlusion." 02/01/1996 - "BACKGROUND: The purpose of the present investigation was to determine if post-ischemic treatment with the 21-aminosteroid lipid peroxidation inhibitor tirilazad mesylate (U-74006F) could affect reperfusion brain edema during the first 3h following a 3h period of middle cerebral artery occlusion-induced focal ischemia in cynomolgus monkeys. " Order ALL the reference details at left...
3.	Ischemia 06/01/1998 - "The lipid peroxidation inhibitor H290/51 attenuated cardiac injury induced by ischemia-reperfusion." 06/01/1995 - "Beneficial effects of H290/51, a new lipid peroxidation inhibitor, on functional recovery after ischemia and reperfusion in isolated cold-arrested rat hearts." 06/01/1995 - "In the present study, a newly synthetized lipid peroxidation inhibitor H290/51 [cis-7methyl-9-methoxy-5,5a,b,10b- tetrahydroindeno(2,1-6 indole)] was evaluated for its effects on myocardial functional recovery during reperfusion after 30-min global ischemia in isolated cold-arrested rat hearts. " 03/15/1998 - "The lipid peroxidation inhibitor indenoindole H290/51 protects myocardium at risk of injury induced by ischemia-reperfusion." 10/03/1994 - "Effects of the lipid peroxidation inhibitor tirilazad mesylate (U-74006F) on gerbil brain eicosanoid levels following ischemia and reperfusion." Order ALL the reference details at left...
4.	Retrograde Degeneration 05/01/1996 - "The purpose of this study was to investigate the role of oxygen radical-induced lipid peroxidative mechanisms in trophic deprivation-induced apoptotic motor neuronal degeneration by testing the ability of the 21-aminosteroid lipid peroxidation inhibitor tirilazad mesylate (U-74006F) to attenuate the retrograde degeneration of facial motor neurons following axotomy in 14-day-old rat pups. " Order ALL the reference details at left...
5.	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 02/01/1996 - "The 21-aminosteroid lipid-peroxidation inhibitor, tirilazad mesylate (U-74006F), recently was shown in a large multinational Phase III clinical trial to decrease mortality and improve neurological recovery in patients 3 months after onset of aneurysmal subarachnoid hemorrhage (SAH). " 06/01/1994 - "The present work aimed at examining the effect of tirilazad mesylate (U74006F), a newly developed lipid peroxidation inhibitor, on the intraluminal narrowing of basilar artery subjected to subarachnoid hemorrhage (SAH) in beagle dogs. " 03/01/1998 - "Tirilazad is a membrane lipid peroxidation inhibitor being studied for the management of subarachnoid hemorrhage; phenytoin is used for seizure prophylaxis in the same disorder. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	tirilazad
2.	U 101033E (U-101033E)
3.	Oxygen
4.	pyrrolopyrimidine
5.	acamprosate (AOTA)
6.	indole
7.	Felodipine (Agon)
8.	Propranolol (Inderal)
9.	Phenytoin (Dilantin)
10.	Phenobarbital (Luminal)

Related Therapies and Procedures

1.	Axotomy

Best Treatments:
Research Summary Report
on Brain Ischemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 543 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>